## CATHETER ABLATION OF ATRIAL FIBRILLATION

Edited by Etienne Aliot

Michel Haïssaguerre Warren M. Jackman



# Catheter Ablation of Atrial Fibrillation

EDITED BY

Etienne Aliot Michel Haïssaguerre Warren M. Jackman



© 2008 by Blackwell Publishing Blackwell Futura is an imprint of Blackwell Publishing

Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia

All rights reserved. No part of this publication may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher, except by a reviewer who may quote brief passages in a review.

First published 2008

1 2008

ISBN: 978-1-4051-6349-1

Library of Congress Cataloging-in-Publication Data

Catheter ablation of atrial fibrillation / edited by Etienne Aliot, Michel Haissguerre, Warren M. Jackman.

p. ; cm.

Includes bibliographical references.

ISBN 978-1-4051-6349-1 (Hbk trade version)

978-1-4051-8665-0 (Customised version, not for trade sale)

1. Catheter ablation. 2. Atrial fibrillation – Surgery. I. Aliot, Etienne. II. Ha?ssaguerre, Michel. III. Jackman, Warren M.

[DNLM: 1. Atrial Fibrillation – surgery. 2. Atrial Fibrillation – therapy. 3. Catheter Ablation – methods. WG 330 C3628 2008]

RD598.35.C39C383 2008

616.1'28-dc22

2007049865

A catalogue record for this title is available from the British Library

Commissioning Editor: Gina Almond Development Editor: Beckie Brand Editorial Assistant: Jamie Hartmann-Boyce Production Controller: Debbie Wyer

Set in 9.5/12 pt Minion by Graphicraft Limited, Hong Kong Printed and bound in Singapore by Fabulous Printers Pte Ltd

For further information on Blackwell Publishing, visit our website: www.blackwellcardiology.com

The publisher's policy is to use permanent paper from mills that operate a sustainable forestry policy, and which has been manufactured from pulp processed using acid-free and elementary chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board used have met acceptable environmental accreditation standards.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

### Catheter Ablation of Atrial Fibrillation

#### Contributors

#### Joseph Akar, MD, PHD

Center for Heart and Cardiovascular Medicine, Loyola University Health System, Maywood, Illinois, USA

#### Etienne Aliot, MD

Department of Cardiology, University of Nancy, Vandoeuvre les Nancy, France

#### Maurits Allessie, MD, PhD

Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

#### Matthias Antz, MD

Oberärztin Magn. Navigation, Hanseatic Heart Center St. Georg, Hamburg, Germary

#### Leonardo Arantès, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Dietmar Bänsch, мр

Oberärztin Magn. Navigation, Hanseatic Heart Center St. Georg, Hamburg, Germany

#### Omer Berenfeld, PhD

Department of Pharmacology and the Institute for Cardiovascular Research, SUNY Upstate Medical University, Syracuse, New York, USA

#### Pierre Bordachar, мр

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Neil Brysiewicz, BSE

Center for Heart and Cardiovascular Medicine, Loyola University Health System, Maywood, Illinois, USA

#### José Angel Cabrera, MD, PhD

Arrhythmia Unit, Hospital Quiron-Madrid, Universidad Europea de Madrid, Madrid, Spain

#### Domenico Caponi, MD

Cardinal Massaia Hospital, Asti, AT Italy

#### Shih-Ann Chen, MD

Division of Cardiology and Cardiovascular Research Center, National Yang-Ming University, School of Medicine and Taipei Veterans General Hospital, Taiwan

#### Julian K.R. Chun, MD

Oberärztin Magn. Navigation, Hanseatic Heart Center St. Georg, Hamburg, Germany

#### Jacques Clémenty, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Lam Dang, PhD

Swiss Federal Institute of Technology, Lausanne, Switzerland

#### D. Wyn Davies, MD, FRCP

St. Mary's Hospital, Waller Department of Cardiology, London, UK

#### Christian de Chillou, MD, PHD

Department of Cardiology, Nancy University Hospital, Nancy, France

#### Natasja de Groot, MD, PHD

Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

#### Isabel Deisenhofer, MD

Deutsches Herzzentrum München, Klinik an der Technischen, Universität München, München, Germany

#### Antoine Deplagne, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Nicolas Derval, MD

Hópital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Sabine Ernst, MD, PHD

Imperial College, National Heart and Lung Institute, Royal Brompton and Harefield Hospital, London, UK

#### Thomas H. Everett, IV, PhD

Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA

#### Jerónimo Farré, MD, PhD, FESC

Department of Cardiology, Fundación Jiménez Díaz-Capio, Universidad Autónoma de Madrid, Madrid, Spain

#### Fiorenzo Gaita, мр

Department of Cardiology, Cardinal Massaia Hospital, Asti, AT, Italy

#### Michel Haïssaguerre, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Siew Yen Ho, PhD, FRCPath

National Heart and Lung Institute, Imperial College and the Royal Brompton and Harefield NHS Trust, London, UK

#### Mélèze Hocini, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Li-Fern Hsu, мв, вs

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Pierre Jaïs, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux. France

#### José Jalife, MD

Department of Pharmacology and Institute for Cardiovascular Research, SUNY Upstate Medical University, Syracuse, New York, USA

#### Bobby John, MD

Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and the Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, Australia

#### Anders Jönsson, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Jérôme Kalifa, мр, РhD

Department of Pharmacology and Institute for Cardiovascular Research, SUNY Upstate Medical University, Syracuse, New York, USA

#### Lukas Kappenberger, MD

CardioMet, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

#### Mohammed Nasir Khan, мр

Cardiovascular Associates, Elk Grove Village, Illinois, USA

#### George J. Klein, мр

University of Western Ontario, University Hospital, London, Ontario, Canada

#### Sébastien Knecht, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Sathish Kodali, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Karl-Heinz Kück, MD

Oberärztin Magn. Navigation, Hanseatic Heart Center St. Georg, Hamburg, Germany

#### **Pawel Kuklik, BSC**

Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and the Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, Australia

#### Dennis H. Lau, MB, BS

Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and the Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, Australia

#### Kang Teng Lim, MB, BS

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Lorraine Mackenzie, PHD

Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and the Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, Australia

#### Seiichiro Matsuo, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Antonio Montefusco, MD

Cardinal Massaia Hospital, Asti, AT, Italy

#### Andrea Natale, MD

Adjunct Professor, Stanford University, Palo Alto, California, USA

#### Stanley Nattel, MD

Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal and Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada

#### Jeffrey E. Olgin, MD

Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA

#### Mark D. O'Neill, MB, BCH, DPHIL

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Feifan Ouyang, MD

Oberärztin Magn. Navigation, Hanseatic Heart Center St. Georg, Hamburg, Germany

#### Carlo Pappone, MD, PHD

Department of Cardiology, Electrophysiology and Cardiac Pacing Unit, San Raffaele Scientific Institute, Milan, Italy

#### Ibrahim Abu Romeh, MD

Heart Failure and Transplant Fellow, University of Utah, Utah, USA

#### Thomas Rostock, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Martin Rotter, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Patrick Ruchat, MD

Service de Chirurgie Cardio-Vasculaire, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

#### Frédéric Sacher, MD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Damián Sánchez-Quintana, MD, PhD

Department of Human Anatomy and Cell Biology, Faculty of Medicine, University of Extremadura, Badajoz, Spain

#### Prashanthan Sanders, MB, BS, PHD

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and the Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, Australia

#### Vincenzo Santinelli, мр

Department of Cardiology, Electrophysiology and Cardiac Pacing Unit, San Raffaele Scientific Institute, Milan, Italy

#### Peter Santucci, MD

Center for Heart and Cardiovascular Medicine, Loyola University Health System, Maywood, Illinois, USA

#### Juerg Schlaepfer, MD

Service de Cardiologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

#### Claus Schmitt, MD

Medizinischen Klinik, Klinikum Karlsruhe, Karlsruhe, Germany

#### Martin K. Stiles, мв, снв

Cardiovascular Research Centre,
Department of Cardiology,
Royal Adelaide Hospital and the Disciplines of
Medicine and Physiology, University of Adelaide,
Adelaide, Australia

#### Rajesh Subbiah, BSC(MED), MB, BS, PHD

Hópital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Yoshihide Takahashi, мр

Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France

#### Hsuan-Ming Tsao, MD

Department of Internal Medicine, National Yang-Ming University Hospital, Taiwan

#### Els Tuyls, MSc

Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

#### Sander Verheule, PhD

Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

#### Nathalie Virag, PhD

Medtronic Europe, Tolochenaz, Switzerland

#### David J. Wilber, MD

Center for Heart and Cardiovascular Medicine, Loyola University Health System, Maywood, Illinois, USA

#### Scott Willoughby, PHD

Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital and the Disciplines of Medicine and Physiology, University of Adelaide, Adelaide, Australia

#### Matthew Wright, MBBS, PHD

St. Mary's Hospital, Waller Department of Cardiology, London, UK

#### Mei-Han Wu, мр

Division of Radiology, National Yang-Ming University, School of Medicine and Taipei Veterans General Hospital, Taiwan

#### Glenn D. Young, мв, вs

Cardiovascular Research Centre,
Department of Cardiology,
Royal Adelaide Hospital and the Disciplines of
Medicine and Physiology,
University of Adelaide,
Adelaide, Australia

#### Introduction

Atrial fibrillation (AF) has long been a field for experimental, pharmacological, and clinical investigations. After initial surgical attempts to cure AF using multiple incisions, the observation that the pulmonary veins were mainly involved in the genesis of AF has promoted the use of catheter techniques for curative approaches.

This book provides a collective text that integrates advances in basic and clinical electrophysiology that have emerged in the last 10 years. Our goal is to produce a treatise that electrophysiologists, allied healthcare professionals, and industry personnel will use as a guide to assist in patient care, to stimulate research projects, and to continue the remarkable advances in the treatment of AF.

A major message appears to be the complexity of underlying factors initiating and perpetuating AF, and the need for combined approaches to involve these different mechanisms. Another message is to acknowledge the limitations of present technologies which, despite achieving dramatic termination of most AF, require additional interventions for tissue recovery or new substrate.

The book is divided into several parts. The first part (Chapters 1–7) is devoted to the fundamental

concepts of AF, origin of signals, computer simulation, and updated reviews of ablation tools. The anatomy chapter is richly illustrated by numerous high quality images. This information is necessary for appropriate clinical practice. The second part (Chapters 8–12) provides the present practical approaches to the ablation of specific targets in the fibrillating atria including pulmonary veins, fragmented electrograms, and linear lesions and details the strategies in paroxysmal or chronic AF or facing left atrial tachycardias. The final part (Chapters 13–18) addresses the special challenge of heart failure patients, the impact of ablation on mortality, atrial mechanical function, and lessons from surgical AF ablation.

Each chapter is written by experienced and internationally recognized authors, most being the leading experts in this field.

We hope that this book may become a reference text for many and will be followed by future editions to provide up to date information in this rapidly developing area.

> Etienne Aliot Michel Haïssaguerre Warren M. Jackman

### Contents

Contributors, vii Introduction, xi

#### Part 1 Fundamental concepts of atrial fibrillation

- 1 Anatomy of the left atrium relevant to atrial fibrillation ablation, 3 José Angel Cabrera, Jerónimo Farré, Siew Yen Ho, Damián Sánchez-Quintana
- 2 Mechanisms and significance of fractionated electrograms recorded during atrial fibrillation, 32 Sander Verheule, Els Tuyls, Natasja de Groot, Maurits Allessie
- 3 Computer simulation studies of atrial fibrillation, 43 Nathalie Virag, Lam Dang, Patrick Ruchat, Juerg Schlaepfer, Lukas Kappenberger
- 4 Experimental and theoretical insights into fundamental mechanisms of antiarrhythmic drug actions on atrial fibrillation: prospects for improved pharmacotherapy, 52 Stanley Nattel
- 5 Mechanisms of atrial fibrillation in animals and humans, 61 Omer Berenfeld, Jérôme Kalifa, José Jalife
- 6 Three-dimensional images in catheter ablation of atrial fibrillation, 75 Hsuan-Ming Tsao, Mei-Han Wu, Shih-Ann Chen

7 Signal processing of fibrillatory electrograms, 85 Thomas H. Everett, IV, Jeffrey E. Olgin

#### Part 2 Practical approaches in atrial fibrillation

- 8 Emerging technologies in the treatment of atrial fibrillation, 105 Matthew Wright, Christian de Chillou, Etienne Aliot, D. Wyn Davies
- 9 Techniques targeting the pulmonary veins, 117 Sabine Ernst, Feifan Ouyang, Matthias Antz, Julian K. R. Chun, Dietmar Bänsch, Karl-Heinz Kück
- 10 Techniques of linear lesion for atrial fibrillation ablation, 124

  Mélèze Hocini, Kang Teng Lim, Prashanthan Sanders, Pierre Jaïs, Mark D. O'Neill, Yoshihide Takahashi, Anders Jönsson, Seiichiro Matsuo, Sébastien Knecht, Leonardo Arantès, Jacques Clémenty, Michel Haïssaguerre
- 11 Ablation strategies in paroxysmal atrial fibrillation, 136 Isabel Deisenhofer, Claus Schmitt
- 12 Ablation strategies in chronic atrial fibrillation, 163
  Mark D. O'Neill, Kang Teng Lim, Pierre Jaïs, Mélèze Hocini, Yoshihide Takahashi, Anders Jönsson, Frédéric Sacher, Prashanthan Sanders, Sathish Kodali, Leonardo Arantès, Seiichiro Matsuo, Sébastien Knecht, Thomas Rostock, Martin Rotter, Jacques Clémenty, George J. Klein, Michel Haïssaguerre

#### Part 3 Special challenges in atrial fibrillation

- 13 Diagnostic algorithm of atrial tachycardia following atrial fibrillation ablation: importance of localized reentries, 193 Pierre Jaïs, Sébastien Knecht, Seiichiro Matsuo, Mark D. O'Neill, Rajesh Subbiah, Leonardo Arantès, Kang Teng Lim, Nicolas Derval, Frédéric Sacher, Antoine Deplagne, Pierre Bordachar, Mélèze Hocini, Jacques Clémenty, Michel Haïssaguerre
- 14 Catheter ablation of atrial fibrillation in patients with heart failure, 212 Ibrahim Abu Romeh, Mohammed Nasir Khan, Andrea Natale
- 15 Morbidity and mortality of ablation versus drugs, 219Carlo Pappone, Vincenzo Santinelli

- 16 Atrial mechanical function after atrial fibrillation ablation, 225
  Prashanthan Sanders, Pierre Jaïs, Glenn D. Young, Frédéric Sacher, Martin Rotter, Mélèze Hocini, Li-Fern Hsu, Martin K. Stiles, Bobby John, Dennis H. Lau, Yoshihide Takahashi, Thomas Rostock, Pawel Kuklik, Lorraine Mackenzie, Scott Willoughby, Michel Haïssaguerre
- 17 Surgery for atrial fibrillation: from scalpel to catheter . . . and back? 233

  Fiorenzo Gaita, Antonio Montefusco, Domenico Caponi, George J. Klein
- 18 Electrogram-guided approach to ablation of atrial fibrillation, 240 David J. Wilber, Joseph Akar, Peter Santucci, Neil Brysiewicz

Index, 257

此为试读,需要完整PDF请访问: www.ertongbook.com



# Fundamental concepts of atrial fibrillation

## 1

#### **CHAPTER 1**

## Anatomy of the left atrium relevant to atrial fibrillation ablation

José Angel Cabrera, Jerónimo Farré, Siew Yen Ho, & Damián Sánchez-Quintana

#### Introduction

Atrial fibrillation (AF) is an arrhythmia most likely due to multiple etiopathogenic mechanisms. In spite of a still incomplete understanding of the anatomofunctional basis for the initiation and maintenance of AF, various radiofrequency catheter ablation (RFCA) techniques have been shown to modify the substrate of the arrhythmia and/or its neurovegetative modulators, achieving in a high proportion of cases a sustained restoration of a stable sinus rhythm [1-26]. Catheter ablation techniques in patients with AF have evolved from an initial approach focused on the pulmonary veins (PVs) and their junctions with the left atrium (LA), to a more extensive intervention mainly, but not exclusively, on the left atrial myocardium and its neurovegetative innervation [27–32]. We firmly believe that progress is still required to refine the currently accepted catheter ablation approaches to AF. Because the LA is the main target of catheter ablation in patients with AF, in this chapter we review the gross morphological and architectural features of this chamber and its relations with extracardiac structures. The latter have also become

relevant because of some extracardiac complications of AF ablation, such as injuries of the phrenic and vagal plexus nerves, or the devastating left atrioesophageal fistula formation [33–40].

#### Components of the left atrium

From a gross anatomical viewpoint the LA has four components: (1) a venous part that receives the PVs; (2) a vestibule that conducts to the mitral valve; (3) the left atrial appendage (LAA); and (4) the so-called interatrial septum. We want to emphasize that the true interatrial septum is the oval fossa, a depression in the right atrial aspect of the area traditionally considered to be the interatrial septum [41–46] (Figures 1.1–1.4). At the left atrial level, a membranous valve covers this region and conceptually represents the only true interatrial septum in the sense that it can be crossed without exiting the heart. The rest of the "muscular interatrial septum" is formed by the apposition of the right and left atrial myocardia that are separated by vascularized fibro-fatty tissues extending from the extracardiac fat. This is why we prefer to use the term interatrial groove rather than muscular interatrial septum, a concept that is not only of academic interest because trans-septal punctures to access the LA should be performed through the oval fossa (Figure 1.2). Thus, a puncture throughout the interatrial groove (the muscular interatrial septum)

Catheter Ablation of Atrial Fibrillation Edited by Etienne Aliot, Michel Haïssaguerre and Warren M. Jackman © 2008 Blackwell Publishing, ISBN: 978-1-4501-6349-1.

**Figure 1.1** External appearances of the right and left atriums viewed from anterior (a), superior (b), and right lateral (c) views. Note the location of the transverse sinus (white dotted lines) and its relationship to the aorta and atrial walls (a, b). The superior and posterior walls of the LA were anchored by the entrance of one PV at each of the

four corners. (c) Site of the interatrial groove (Waterston's groove, blue dotted line). AO, aorta; LAA, left atrial appendage; LIPV, left inferior pulmonary vein; LSPV, left superior PV; PT, pulmonary trunk; RAA, right atrial appendage; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein; SCV, superior caval vein.




Figure 1.2 (a) Four-chamber section through the heart showing the offset arrangement of the mitral valve (MV) and tricuspid valve (TV) which produces the so-called muscular atrioventricular septum (\*) and the deep infolding of the atrial wall superior to the floor of the oval fossa (dotted lines). The true septal area is considerably smaller. (b) The cardiac base (short axis) is dissected by removing most of the atrium's aspects. The right pectinate

muscles skirt around the vestibule of the right atrium and reach the orifice of the coronary sinus. Note that the pectinate muscles in the LA are limited mostly within the appendage and the dotted line marking the vestibule of the mitral annulus. CSo, coronary sinus orifice; ICV, inferior caval vein; LAA, left atrial appendage; PA, pulmonary artery; RAA, right atrial appendage.

may result in hemopericardium in a highly anticoagulated patient because blood will dissect the vascularized fibro-fatty tissue that is sandwiched between the right and left atrial myocardium at this level [47–49].

The major part of the endocardial LA including the septal and interatrial groove component is relatively smooth walled. The left aspect of the interatrial groove, apart from a small crescent-like edge, is almost indistinguishable from the parietal atrial wall. The smoothest parts are the superior and posterior walls, which make up the pulmonary venous component, and the vestibule surrounding the mitral orifice. Behind the posterior portion of




Figure 1.3 (a) Dissection of the posterior wall of the LA close to Waterston's groove. The smooth-walled venous component of the LA is the most extensive. The septal aspect of the LA shows the crescentic line of the free edge (dotted line) of the flap valve against the rim of the oval fossa. (b) The orifices of the right superior and inferior

pulmonary veins (RSPV and RIPV) are adjacent to the plane of the septal aspect of the LA (dotted line). The dashed blue line marks the hinge of the mitral valve. LAA, left atrial appendage; LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary vein.




Figure 1.4 Longitudinal sections through the left atrial appendage (LAA) showing the orifices of the right PV; the flap valve of the oval fossa overlaps (arrows) the rim to form the septal aspect of the LA. Note the relation of the superior caval vein (SCV) to the right superior pulmonary

vein (RS). (b) Longitudinal section to show the relationship of the roof of the left atrium with the right pulmonary artery (RPA) and right bronchus. Ao, aorta; CS, coronary sinus; MV, mitral valve; PT, pulmonary trunk; RI, right inferior pulmonary vein; RS, right superior pulmonary vein.

the vestibular component of the LA is the anterior wall of the coronary sinus [41] (Figures 1.3 and 1.4).

#### The walls of the left atrium and the septum

#### The left atrial wall and its thickness

The walls of LA, excluding the LAA, can be described as anterior, superior, left lateral, septal, and posterior. The anterior wall is located behind the ascending aorta and the transverse pericardial sinus. From epicardium to endocardium its width is  $3.3 \pm 1.2$  mm (range 1.5-4.8 mm) in unselected necropsic heart specimens, but this wall can become very thin at the area near the vestibule of the mitral annulus where it measures an average of 2 mm in thickness in our autopsy studies. The roof or superior wall of the LA is in close proximity to

the right pulmonary artery and its width ranges from 3.5 to 6.5 mm (mean  $4.5 \pm 0.6$  mm). The thickness of the lateral wall ranges between 2.5 and 4.9 mm (mean  $3.9 \pm 0.7$  mm) [41].

As already stated, an anatomic septum is like a wall that separates adjacent chambers so that perforation of a septal wall would enable us to enter from a chamber to the opposite one without exiting the heart. Thus, the true atrial septal wall is confined to the flap valve of the oval fossa. The flap valve is hinged from the muscular rim that, deriving from the septum secundum, is seen from the right atrial aspect of the interatrial wall. At its anteroinferior portion the rim separates the foramen ovale from the coronary sinus and the vestibule of the tricuspid valve [48] (Figure 1.2). On the left atrial aspect there is no visible rim and the flap valve overlaps the oval rim quite considerably and two horns mark the usual site of fusion with the rim (Figure 1.3 and 1.4). The measurement of the mean thickness of the atrial septum in normal hearts at the level of the anteroinferior portion of the muscular rim is  $5.5 \pm$ 2.3 mm, and the mean thickness of the flap valve is  $1.5 \pm 0.6$  mm [41]. These results agree with previously published echocardiographic studies [50]. The major portion of the rim around the fossa is an infolding of the muscular atrial wall that is filled with epicardial fat. Superiorly and posteriorly there is an interatrial groove, also known as Waterston's groove, whose dissection permits the separation of the right and left atrial myocardial walls and to enter the LA without transgressing into the right atrium. Anteriorly and inferiorly, the rim and its continuation into the atrial vestibules overlies the myocardial masses of the ventricles from which they are separated by the fat-filled inferior pyramidal space [48,51] (Figures 1.2-1.4).

The posterior wall of the LA is a target of currently used ablation procedures in patients with AF. Early surgical interventions aimed at reducing the critical mass of atrial tissues created long transmural linear lesions incorporating the posterior LA wall. The posterior wall of the LA is related to the esophagus and its nerves (vagal nerves) and the thoracic aorta, and its inferior portion is related to the coronary sinus. In a previous study in 26 unselected human heart specimens the overall thickness of the posterior LA wall was  $4.1\pm0.7$  mm (range 2.5-5.3 mm) [41]. In a subsequent study we

measured the thickness of the posterior wall from the epicardium to endocardium, obtaining sagittal and transverse sections through the LA at three levels (superior, middle, and inferior close to the coronary sinus) in three different LA regions (right venoatrial junction, mid-posterior atrial wall, and left venoatrial junction) [52]. We also analyzed the myocardial content of the LA wall at all these predefined sites. The region with the thickest myocardial content was the mid-posterior LA wall ( $2.9 \pm 0.5$  mm, range 0.6-4.2 mm). The inferior level, immediately superior to the coronary sinus and between 6 and 15 mm from the mitral annulus, had the thickest posterior LA wall  $(6.5 \pm 2.5 \text{ mm}, \text{range } 2.8-12 \text{ mm})$ . The latter thickness was due to a rather bulky myocardial layer  $(4.3 \pm 0.8 \text{ mm})$  and the presence of a profuse amount of fibro-fatty tissue, both components being less developed at more superior levels of the posterior LA wall. The wall at the plane of the right or left venoatrial junction had the thinnest musculature (2.2  $\pm$  0.3 mm, range 1.2–4.5 mm) and a very scanty content of fibro-fatty tissue [52]. In some samples of histological sections obtained at the PV and posterior atrial wall, the myocardial layer had small areas of discontinuities that were filled with fibrous tissue [42,53].

#### The myoarchitecture of the left atrial wall

Detailed dissections of the subendocardial and subepicardial myofibers along the entire thickness of the LA walls have shown a complex architecture of overlapping bands of aligned myocardial bundles [41,51] (Figures 1.5 and 1.6). The term "fibers" describes the macroscopic appearance of strands of cardiomyocytes. These fibers are circumferential when they run parallel to the mitral annulus and longitudinal when they are approximately perpendicular to the mitral orifice. Although there are some individual variations, our epicardial dissections of the LA have shown a predominant pattern of arrangement of the myocardial fibers [41]. On the subepicardial aspect of the LA, the fibers in the anterior wall consisted of a main bundle that was parallel to the atrioventricular groove. This was the continuation of the interatrial bundle (Bachmann's bundle) [54], which could be traced rightward to the junction between the right atrium and the superior caval vein. In the LA, the interatrial bundle